Navigation Links
Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
Date:5/29/2008

COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's investigational 13-valent pneumococcal conjugate vaccine for infants and toddlers. Wyeth is seeking a pediatric indication for active immunization against invasive pneumococcal disease (IPD) and otitis media caused by serotypes included in the vaccine. The vaccine includes six new serotypes (1, 3, 5, 6A, 7F and 19A) in addition to the seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) included in PREVNAR(R), Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), also known as PCV7.

"While the incidence of pneumococcal disease has been substantially reduced since our introduction of PREVNAR in the United States, pneumococcal disease remains a health threat to children, specifically as emerging strains, such as 19A, become more prevalent," says Emilio Emini, Ph.D., Executive Vice President, Vaccine Research and Development, Wyeth Pharmaceuticals. "With that in mind, we are very pleased that the FDA has granted Fast Track designation to our investigational 13-valent vaccine for pediatric use."

Fast Track designation is designed to facilitate review of products that address serious or potentially life threatening conditions for which there is an unmet medical need. With Fast Track designation, Wyeth plans to submit the biologics license application on a rolling basis as sections of the application are completed, enabling the FDA to begin review sooner.

The Company expects to complete its U.S. filing for pediatric use of the vaccine in the first quarter of 2009. Wyeth is also exploring oppo
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
2. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
3. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
4. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
7. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
11. Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Calif. , Feb. 27, 2015  Finesse expands office ... Finesse Solutions announced the expansion of its operations ... is planned for mid-March and access for customers is ... the A-563, and located adjacent to the current office, ... the Finesse automation engineering team and allow Finesse to bring ...
(Date:2/26/2015)... 26, 2015  AbbVie (NYSE: ABBV ... in its neuroscience and oncology development programs have ... American Academy of Neurology annual meeting in ... 18-25. The accepted abstracts feature results from studies ... investigational treatments in AbbVie,s pipeline. Presentations will include ...
(Date:2/26/2015)... 26, 2015  Mobility Ventures LLC, an AM General ... of America (NYSE: BAC ) that will ... of the revolutionary MV-1 - - the world,s first ... up to provide safe and comfortable transportation for all ... loan to purchase a new MV-1 vehicle at the ...
Breaking Medicine Technology:New Finesse Office in United Kingdom 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... VIEW, Calif., July 24 Alexza,Pharmaceuticals, Inc. ... it has initiated,its second Phase 3 clinical ... inhalation product candidate being developed for the ... or bipolar disorder.,Alexza believes the novel, non-invasive ...
... Program Speeds Oncology Patient Accrual, DENVER, ... Management,Organization (RMO), has contracted with five leading ... services for their,clinical trials using the Just-in-Time ... following disease indications: follicular Non-Hodgkin,s,Lymphoma, Metastatic Breast ...
Cached Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2
(Date:2/28/2015)... Malaysia (PRWEB) February 28, 2015 The ... all across Malaysia into one platform and gears towards ... , A series of group talks in smaller ... like Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, ... and raise awareness of Malaysian youths. , ...
(Date:2/28/2015)... 28, 2015 Gerald “Solutionman” Haman surveyed ... or barriers to innovative thinking. “The #1 block ... lack of tools,” reports Haman, who created the Thinkubator ... of people felt that they did not have enough ... and resources to stimulate innovation. , Solutionman’s monthly “Accelerating ...
(Date:2/28/2015)... March—also known as National Brain Injury ... and others that suspected head injuries, especially concussions, ... , Concussions are a form of traumatic brain ... There are 1.6-3.8 million sports-related concussions per year. ... is a brain injury. Many athletes suffer knee ...
(Date:2/28/2015)... A study out of the University of Oxford ... the treatment of a hereditary ocular condition that leads ... Dr. Robert MacLaren, professor of ophthalmology at the University ... on January 16, 2014 , the study treated six ... mostly affects men and leads to the degeneration of ...
(Date:2/28/2015)... Louis, MO (PRWEB) February 28, 2015 ... leading provider of outsourced sales, marketing and supply ... their client, BIOTA Botanicals, is bringing its award ... Celebrated worldwide, BIOTA Botanicals’ products are specifically created ... herbal care experts, BIOTA is committed to marrying ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... Center for Photomedicine at Massachusetts General Hospital (MGH) ... imaging technology optical coherence tomography (OCT) that can ... disease. In a Nature Medicine ... how microOCT which provides 10 times greater ...
... has been known to cause an assortment of health problems, ... for Sports Medicine,s (AOSSM) Annual Meeting in San Diego today, ... chance of muscle injuries in athletes, specifically NFL football players. ... vitamin D insufficiency. African American players and players who suffered ...
... , SUNDAY, July 10 (HealthDay News) -- ... for many Americans, but mixing the two can be ... warns. Alcohol is involved in half of all ... the NIAAA, which outlined a number of potentially dangerous ...
... have identified a group of patients who may have increased ... that usually develops because a teenager or young adult has ... study will be presented at the annual meeting of the ... in San Diego. "The conclusion from this study is ...
... SATURDAY, July 9 (HealthDay News) -- A bit of ... get enough exercise during the summer, experts say. To ... of one hour of physical activity a day, suggested Dr. ... of Alabama at Birmingham. "Set an expectation of doing ...
... Surgery have found that in comparison to open surgery, ... to arthritis produces similar outcomes in terms of repairing ... published in the July 2011 TK issue of the ... of patients with more typical hip impingement, arthroscopic approaches ...
Cached Medicine News:Health News:High-resolution imaging technology reveals cellular details of coronary arteries 2Health News:Study identifies patients who should not undergo surgery for a snapping hip tendon 2Health News:Study identifies patients who should not undergo surgery for a snapping hip tendon 3Health News:Help Your Kids Stay in Shape This Summer 2Health News:Arthroscopy and open surgery are equally efficacious in treating common hip problem in most patients 2Health News:Arthroscopy and open surgery are equally efficacious in treating common hip problem in most patients 3
ROC XS is a polyethylene implant used for soft tissue reattachment to bone. The umbrella-like deployment of this anchor provides increased fixation strength. This anchor is easy-to-insert using the R...
The Knotless Anchor, a titanium alloy implant, is used for soft tissue reattachment to bone. The Knotless Anchor is indicated for open and arthroscopic Bankart repairs....
... The Linvatec 5mm Super Revo Suture Anchor ... arthroscopic or a mini-open rotator cuff repair. ... the anchor is pre-threaded with two #2 ... pitfalls of suture management are avoided with ...
The 4mm diameter Revo suture anchor is designed primarily for arthroscopic and open rotator cuff repair. Additional applications include other shoulder repair procedures, as well as use in knees and ...
Medicine Products: